Drs. Allen Seftel and Serge Carrier talk about whether or not urologists should screen for CVD and risk factors in patients with ED.
Men with erectile dysfunction (ED) have a higher prevalence of metabolic syndrome than those without ED.
A new study looking at the use of opioids suggests that long-term use may be associated with a significantly higher risk of ED.
Men with erectile dysfunction (ED) have a higher prevalence of metabolic syndrome than those without ED.
Dose and duration of opioid use associated with increased odds of erectile dysfunction.
Under-treatment persists despite heavy promotion in the media.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
Tadalafil plus finasteride improved symptoms scores better than finasteride plus placebo.
Following surgery, symptom severity declined significantly and remained stable over 10 years.
Improvements in penile curvature deformity, Peyronie's disease bother score.
RLS increases the risk by 38%, data show.
In a study, CRP levels were significantly higher among ED sufferers who did not respond to tadalafil.
Herpes simplex virus infection is independently associated with a nearly threefold increased risk.
The drug, which is approved for treating men with erectile dysfunction, benign prostatic hyperplasia, or both conditions, also improved orgasmic function.
Men with erectile dysfunction (ED) are more likely to have chronic periodontitis than those without ED.
Adding testosterone therapy to sildenafil is not more effective in treating erectile dysfunction (ED) than sildenafil alone,
Significantly more 30- to 40-year-old males with erectile dysfunction have chronic periodontitis
Management of ED may improve adherence, treatment outcomes, decrease healthcare costs.
